Treatment with the thymic polypeptide fraction Biomodulina T potentiates immune responses in older adults and cancer patients: an overview of the most recent studies

Biomodulina T: an overview of the most recent studies




immunosenescence, aging, non-small cell lung cancer, immune restoration


Over the past 50 years, the world has experienced a progressive demographic shift resulting in a higher proportion of older adults in the general population. Aging itself is a complex biological phenomenon, characterized in part by changes in the immune system, known as "immunosenescence," that make older adults more susceptible to infections, cardiovascular and autoimmune diseases, and cancer. Several strategies have been proposed to reverse immunosenescence. These include the use of hormones, cytokines, and thymic factors.  Biomodulina T (BT) is a polypeptide fraction derived from bovine thymus. Intervention with BT expands naïve CD4+ T cells while decreasing the frequency of CD4+ and CD8+ T cells expressing PD1 in older adults and patients diagnosed with advanced lung cancer. This brief review aims to present the most recent evidence on the effect of BT on the immune system in older adults and patients diagnosed with advanced lung cancer.


Suárez-Formigo GM, Saavedra-Hernández D. Biomodulina T May Restore Immunity in Older Adults. MEDICC review, 2020; 22(3):54-6.

Saavedra D, Añé-Kourí AL, Barzilai N, et al. Aging and chronic inflammation: highlights from a multidisciplinary workshop. Immunity & ageing : I & A, 2023; 20(1):25.

Pawelec G, Bronikowski A, Cunnane SC, et al. The conundrum of human immune system "senescence". Mechanisms of ageing and development, 2020; 192:111357.

Fulop T, Larbi A, Dupuis G, et al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Frontiers in immunology, 2017; 8:1960.

Fulop T, Larbi A, Pawelec G, et al. Immunology of Aging: the Birth of Inflammaging. Clinical reviews in allergy & immunology, 2021:1-14.

Akbar AN, Henson SM, Lanna A. Senescence of T Lymphocytes: Implications for Enhancing Human Immunity. Trends in immunology, 2016; 37(12):866-76.

Kocarnik JM, Compton K, Dean FE, et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA oncology, 2022; 8(3):420-44.

Fulop T, Larbi A, Kotb R, et al. Aging, immunity, and cancer. Discovery medicine, 2011; 11(61):537-50.

Saavedra D, García B, Lorenzo-Luaces P, et al. Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients. Cancer immunology, immunotherapy : CII, 2016; 65(1):37-45.

Lang PO, Govind S, Aspinall R. Reversing T cell immunosenescence: why, who, and how. Age (Dordrecht, Netherlands), 2013; 35(3):609-20.

Cardinale A, De Luca CD, Locatelli F, et al. Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy. Frontiers in immunology, 2021; 12:752042.

Longo VD, Antebi A, Bartke A, et al. Interventions to Slow Aging in Humans: Are We Ready? Aging cell, 2015; 14(4):497-510.

Saavedra D, Fuertes SA, Suárez GM, et al. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Experimental gerontology, 2019; 124:110633.

Suárez GM, Catalá M, Peña Y, et al. Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Frontiers in oncology, 2022; 12:823287.

Caruso C, Ligotti ME, Accardi G, et al. An immunologist's guide to immunosenescence and its treatment. Expert review of clinical immunology, 2022; 18(9):961-81.

Fülöp T, Dupuis G, Witkowski JM, et al. The Role of Immunosenescence in the Development of Age-Related Diseases. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 2016; 68(2):84-91.

Libri V, Azevedo RI, Jackson SE, et al. Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4+CD45RA+CD27+ T cells: the potential involvement of interleukin-7 in this process. Immunology, 2011; 132(3):326-39.

Pawelec G. Hallmarks of human "immunosenescence": adaptation or dysregulation? Immunity & ageing : I & A, 2012; 9(1):15.

Fulop T, McElhaney J, Pawelec G, et al. Frailty, Inflammation and Immunosenescence. Interdisciplinary topics in gerontology and geriatrics, 2015; 41:26-40.

Pawelec G, Derhovanessian E, Larbi A, et al. Cytomegalovirus and human immunosenescence. Reviews in medical virology, 2009; 19(1):47-56.

Frasca D, Diaz A, Romero M, et al. B Cell Immunosenescence. Annual review of cell and developmental biology, 2020; 36:551-74.

Pawelec G. Immunosenescence and cancer. Biogerontology, 2017; 18(4):717-21.

Wolf E, Milazzo S, Boehm K, et al. Thymic peptides for treatment of cancer patients. The Cochrane database of systematic reviews, 2011; 2011(2):Cd003993.

Costanzi JJ, Gagliano RG, Delaney F, et al. The effect of thymosin on patients with disseminated malignancies. A phase I study. Cancer, 1977; 40(1):14-9.<14::AID-CNCR2820400105>3.0.CO;2-O

Goldstein AL. History of the discovery of the thymosins. Annals of the New York Academy of Sciences, 2007; 1112:1-13.

Rodriguez Martin RR, Gonzalez Gonzalez O, Rodriguez Gonzalez C, et al. History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications. International immunopharmacology, 2023; 119:110167.

CECMED – (Center for State Control of Medications EaMD. [Internet]. Havana: CECMED; Registros. Resumen de las características del producto Biomodulina T; [cited 2024 Feb 18]. Available at: Spanish. 2023.

Orihuela MG, Martínez RS, González IC, et al. Efecto terapéutico de la biomodulina T homeopática con pacientes portadores de enfermedad pulmonar obstructiva crónica. 2011; 10(3):287-95.

Christian López LdlC, Rodríguez Marín RR, Rabassa Pérez J, et al. Efecto de la biomodulina T 1000 sobre el timo en niños con infecciones recurrentes. 2000; 72(1):3-9.

Morales LAG, Rodríguez RFL, Martín RR, et al. Estudio Fase II de tratamiento de pacientes con Esclerosis múltiple exacerbante-remitente con Biomodulina T. 2007; 8(1):28-31.

Cañete R, Afonso JA, Brito K. The Effects of the Uncontrolled Use of Biomodulina T on the Severity of Severe Acute Respiratory Syndrome-Coronavirus 2 Infection in Older Cuban Adults: An Open Label Evaluation. Current therapeutic research, clinical and experimental, 2022; 96:100662.

Hernández IC, Suárez VM, Ramos EH, et al. BIOMODULINA T® Modulates Lymphocyte Compartments in Institutionalized Cuban Geriatric Patients[J]. Journal of Cellular Immunology, 2022, 4(2): 79-91.

Ramos EH, Suárez VM, Hernández IC, et al. Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adults. Experimental gerontology, 2021; 153:111497.

Majumdar S, Nandi D. Thymic Atrophy: Experimental Studies and Therapeutic Interventions. Scandinavian journal of immunology, 2018; 87(1):4-14.

Fülöp T, Larbi A, Hirokawa K, et al. Immunosupportive therapies in aging. Clinical interventions in aging, 2007; 2(1):33-54.

Sportès C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. The Journal of experimental medicine, 2008; 205(7):1701-14.

Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood, 2012; 120(24):4882-91.

Chen IH, Lai YL, Wu CL, et al. Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection. Cancer immunology, immunotherapy : CII, 2010; 59(2):323-34.

Velardi E, Tsai JJ, van den Brink MRM. T cell regeneration after immunological injury. Nature reviews Immunology, 2021; 21(5):277-91.

Suárez GM, Añé-Kourí AL, González A, et al. Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer. Cancer immunology, immunotherapy : CII, 2021; 70(6):1735-43.

Bailur JK, Pawelec G, Hatse S, et al. Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. Breast cancer research : BCR, 2017; 19(1):20.

Sun DP, Wang L, Ding CY, et al. Investigating Factors Associated with Thymic Regeneration after Chemotherapy in Patients with Lymphoma. Frontiers in immunology, 2016; 7:654.

Sfikakis PP, Gourgoulis GM, Moulopoulos LA, et al. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. European journal of clinical investigation, 2005; 35(6):380-7.

Saavedra D, Crombet T. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Frontiers in immunology, 2017; 8:269.

Rodriguez PC, Popa X, Martínez O, et al. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016; 22(15):3782-90.